Drugs / PMC-403
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05953012 | Jul 2023 → Aug 2025 | wet macular degeneration | PharmAbcine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMC-403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05953012 ↗ |
| Route | Intravitreal | “PMC-403 will be administered Intravitreal.” NCT05953012 ↗ |